Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Impact of CAR-T cells expansion and tumor burden on the outcome after inotuzumab ozogamicin as bridging therapy in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia.

Patricia Alcalde-Mellado, Victoria Ruiz-Maldonado, Javier Delgado Serrano, Laura Perez-Ortega, Marta Reinoso -Segura, Luzalba Sanoja Flores, Belén Sierro, Estefania Garcia-Guerrero, Concepción Pérez de Soto, José María Pérez Hurtado, José González-Campos, José Antonio Pérez-Simón, Agueda Molinos-Quintana, Teresa Caballero

Blood (2025) 146 (Supplement 1): 2324.

https://doi.org/10.1182/blood-2025-2324

Published: 2025

Journal Articles

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Blood (2025) 146 (Supplement 1): 371.

https://doi.org/10.1182/blood-2025-371

Published: 2025

Journal Articles

Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation.

Beatriz Chiclana-Rodríguez, Marta García Culebras, Patricia Alcalde-Mellado, Nancy Rodriguez-Torres, Lucía Mezquita Romero, Juan Luis Reguera, Javier Camuña Correa, Estrella Carrillo-Cruz, Marta Reinoso -Segura, Eusebio Martín Chacón, Laura Pérez Ortega, Jose Francisco Falantes, Cristina Blazquez Go I, Francisco Manuel Martin-Dominguez, Maria Eva Mingot, Virginia Escamilla Gomez, José Antonio Pérez-Simón

Blood (2025) 146 (Supplement 1): 4061.

https://doi.org/10.1182/blood-2025-4061

Published: 2025

Journal Articles

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Blood (2025) 146 (Supplement 1): 2238.

https://doi.org/10.1182/blood-2025-2238

Published: 2025

Journal Articles

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Marta Lasa, Esperanza Martin-Sanchez, Aintzane Zabaleta, Diego Alignani, Carmen Gonzalez, Noemi Puig, Elena Alejo, Jorge Labrador, Maria Casanova Espinosa, Laura Rosiñol Dachs, Sebastián Garzón, Enrique Ocio, Albert Pérez-Montaña, Irene Romera, Carmen Couto, Sunil Lakhwani, Felipe Prosper, Adrian Alegre, Elena Cabezudo, Itziar Carro, Cristina Motlló, Montserrat Cortes, Isabel Maria Garcia Cabrera, Marta Romera, Javier de la Rubia, Andrea Manubens, Alexia Suarez Cabrera, Fernando Escalante Barrigón, Carlos Aguilar-Franco, Raquel Del Campo, Maria Esther Clavero Sanchez, Joaquin Martinez-Lopez, Valentin Cabanas Perianes, María-Jesús Blanchard, Ana Lopez-Guia, Diana Sanchez Arguello, Albert Oriol, Marta Reinoso -Segura, María Lourdes Amador Barciela, Celina Benavente Cuesta, Jose Maria Arguiñano PEREZ, Beatriz Ordoñez, Francisco Taboada, Joan Batista Blade Creixenti, María-Victoria Mateos, Juan-Jose Lahuerta Palacios, Jesus San-Miguel, Bruno Paiva

Blood (2025) 146 (Supplement 1): 578.

https://doi.org/10.1182/blood-2025-578

Published: 2025

Journal Articles

Detection, Monitoring and Cell Kinetics of Circulating CAR-T Cells in B-Cell Malignancies

Belén Sierro, Clara Beatriz Garcia-Calderon, Luzalba Sanoja-Flores, Victoria Ruiz-Maldonado, Javier Delgado Serrano, Agueda Molinos-Quintana, Juan Luis Reguera, Beatriz Guijarro-Albaladejo, Marta Reinoso-Segura, Estefania Garcia-Guerrero, Jose A. Perez-Simon, Teresa Caballero

Blood (2022) 140 (Supplement 1): 7550–7551.

https://doi.org/10.1182/blood-2022-163106

Published: 2022

Journal Articles

Stem Cells and Leukemic Stem Cells As a Prognostic Factor in Acute Myeloid Leukemia

Olga Pérez-López, Marta Reinoso Segura, Clara B. Calderon Garcia, Noelia González-Carrasco, María Solé, Eduardo Rodriguez Arboli, Concepción Prats-Martín, Jose González Campos, Jose A. Perez-Simon, Teresa Caballero

Blood (2022) 140 (Supplement 1): 3446–3447.

https://doi.org/10.1182/blood-2022-169528

Published: 2022

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Blood (2022) 140 (Supplement 1): 292–294.

https://doi.org/10.1182/blood-2022-159606

Published: 2022

Journal Articles

Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Teresa Caballero, Olga Pérez-López, Ana Yeguas Bermejo, Eduardo Rodriguez Arbolí, Enrique Colado Varela, Maria Desamparados Sampere Talens, María Belén Vidriales, Covadonga Quirós Caso, Marta Reinoso Segura, Concepción Prats-Martín, Pau Montesinos, Jose A. Perez-Simon

Blood (2021) 138 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2021-151533

Published: 2021

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2021) 138 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2021-148423

Published: 2021

Journal Articles

Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study

Paula Rodríguez-Otero, Veronica Gonzalez De La Calle, Anna Sureda, Felipe De Arriba, Marta Reinoso Segura, Paz Ribas, Ana Pilar Gonzalez, Yolanda Gonzalez-Montes, Albert Oriol, Joaquín Martínez-López, Marta Sonia Gonzalez, Miguel T Hernández, Maialen Sirvent, Joan Bladé Creixenti, Juan Jose Lahuerta, Jesús F. San-Miguel, Maria-Victoria Mateos

Blood (2021) 138 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2021-147725

Published: 2021

Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

Marcelo Capra, MD PhD, Thomas Martin, III, MD, Philippe Moreau, MD, Ross Baker, MBBS, FRACP, FRCPA, BSc, Ludek Pour, MD, Chang-Ki Min, MD PhD, Xavier Leleu, MD, Mohamad Mohty, MD PhD, Marta Reinoso Segura, Mehmet Turgut, MD, Richard Leblanc, MD FRCPC, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136415

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Impact of CAR-T cells expansion and tumor burden on the outcome after inotuzumab ozogamicin as bridging therapy in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia.

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation.

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Detection, Monitoring and Cell Kinetics of Circulating CAR-T Cells in B-Cell Malignancies

Stem Cells and Leukemic Stem Cells As a Prognostic Factor in Acute Myeloid Leukemia

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only